Janus Henderson Group
ZNTL icon

Janus Henderson Group’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Janus Henderson Group’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-21,172
Closed -$86.7K – 2559
2024
Q2 		$86.7K Sell
21,172
-285
-1% -$3.18K ﹤0.01% 2506
2024
Q1 		$338K Buy
21,457
+2
+0% +$28 ﹤0.01% 2185
2023
Q4 		$325K Sell
21,455
-44
-0.2% -$642 ﹤0.01% 2200
2023
Q3 		$431K Buy
21,499
+11
+0.1% +$279 ﹤0.01% 2006
2023
Q2 		$606K Buy
21,488
+36
+0.2% +$864 ﹤0.01% 1872
2023
Q1 		$369K Buy
21,452
+10,999
+105% +$223K ﹤0.01% 2183
2022
Q4 		$210K Sell
10,453
-10,451
-50% -$225K ﹤0.01% 2165
2022
Q3 		$454K Buy
20,904
+10,452
+100% +$286K ﹤0.01% 2003
2022
Q2 		$295K Buy
+10,452
New +$277K ﹤0.01% 2090

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Janus Henderson Group's ZNTL Position: Q3 2024 in Review

Janus Henderson Group sold out of Zentalis Pharmaceuticals (ZNTL) in Q3 2024, closing a stake of 21,172 shares — an estimated $86.7K sold.

Janus Henderson Group first reported a position in ZNTL in Q2 2022 and held it in 9 quarters. The position peaked at $606K in Q2 2023. 136 funds tracked by Wall St. Rank hold ZNTL as of Q3 2024.

  • Janus Henderson Group reported no remaining Zentalis Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Janus Henderson Group sold 21,172 Zentalis Pharmaceuticals shares in Q3 2024, an estimated $86.7K.
  • Janus Henderson Group first reported a position in Zentalis Pharmaceuticals in Q2 2022 and held it in 9 quarters.
  • Janus Henderson Group's Zentalis Pharmaceuticals position peaked at $606K in Q2 2023.
  • 136 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q3 2024.

Based on Janus Henderson Group's 13F filing for Q3 2024, filed 14 Nov 2024.